- DBV Technologies (NASDAQ:DBVT) announces the following changes to its leadership team:
- DBV's Chief Scientific Officer, Dr. Hugh Sampson, will assume the role of interim Chief Medical Officer effective today. Dr. Sampson succeeds Dr. Lucia Septien-Velez, who has decided to leave to pursue other opportunities. Dr. Sampson will lead both the scientific and medical teams and will report to Daniel Tassé, CEO.
- Julie O'Neill, has been engaged effective immediately to direct all product development and process optimization at the Company. She will continue serving as a director, while overseeing the anticipated resubmission of the Viaskin Peanut BLA in children four to 11 years of age.
- Most recently, Julie was Executive VP, Global Operations for Alexion Pharmaceuticals (NASDAQ:ALXN).
- Alan Kerr, Senior VP, Head of Global Regulatory Affairs of DBV Technologies, will now report to the Company's CEO, Daniel Tassé, effective immediately.
- Shares are up 14% premarket.
- Now read: Aimmune Therapeutics: Keep Your Eyes Peeled
Original article